What is the translation of " PROGRAF " in English?

• prograf

Examples of using Prograf in Croatian and their translations into English

Advagraf se ne može zamijeniti Prografom i obrnuto.
Advagraf and Prograf are not interchangeable.

Dr. Parker, uradite prograf i CMP i obavjestite dr. Pirsa.
Dr. Parker, get a prograf and a CMP and keep Dr. Pierce updated.

Dvanaestomjesečno preživljenje presatka iznosilo je 96,7% za Advagraf, 92,9% za Prograf i 95,7% za ciklosporin.
Month graft survival was 96.7% for Advagraf, 92.9% for Prograf and 95.7% for ciclosporin.

Primjer: ukupna dnevna doza Prograf kapsula daje se kao 1 mg ujutro i 0, 5 mg navečer.
Example: Total daily dose Prograf capsules given as 1 mg in the morning and 0.5 mg in the evening.

Preporuke za doze kod transplantacije pluća, gušterače i crijeva temelje se na ograničenim podacima iz prospektivnih kliničkih ispitivanja formulacije Prograf.
The dose recommendations for lung, pancreas and intestinal transplantation are based on limited prospective clinical trial data with the Prograf formulation.

Prelazak između Modigrafa i Prografa kao formulacija takrolimusa.
Conversion between Modigraf and Prograf tacrolimus formulations.

Odnos između najnižih razina takrolimusa(C12) i sistemske izloženosti(AUC0-12) sličan je za obje formulacije takrolimusa, Modigraf granule i Prograf kapsule.
The relationship between tacrolimus trough levels(C12) and systemic exposure(AUC0-12) is similar between the 2 formulations Modigraf granules and Prograf capsules.

Envarsus je dokazano barem jednako učinkovit kao Prograf prema dvije glavne studije provedene na bolesnicima s presađenim bubrezima.
Envarsus has been shown to be at least as effective as Prograf in two main studies in patients with kidney transplants.

Rezultati ispitivanja bioekvivalencije s jednom dozom u odraslih zdravih dobrovoljaca pokazali su da Modigraf granule imaju približno 20% veću bioraspoloživost nego Prograf kapsule.
Results of a single dose bioequivalence study with adult healthy volunteers showed that Modigraf granules were approximately 20% more bioavailable than the Prograf capsules.

U drugoj studiji napravljena je usporedba Envarsusa s Prografom kao dijelom standardnog liječenja 543 bolesnika s novopresađenim bubrezima.
The second study compared Envarsus with Prograf as part of standard treatment in 543 patients with a newly transplanted kidney.

Stopa centralno interpretiranog akutnog odbacivanja presatka potvrđenog biopsijom(BPAR) tijekom 360 dana ispitivanja bila je 13,1% u Envarsus skupini(N 268), a 13,5% u Prograf skupini N 275.
The event rate for centrally-read, biopsy-confirmed acute rejection(BPAR) during the 360-day study was 13.1% in the Envarsus group(N=268) and 13.5% in the Prograf group N=275.

Studije uspoređuju Envarsus s Prografom, široko korištenim i dobro utvrđenim lijekom s akrolimusom koji takrolimus otpušta brže.
These studies compared Envarsus with Prograf, a widely used and well-established tacrolimus medicine that releases tacrolimus more quickly.

U zdravih je ispitanika sistemska izloženost takrolimusu(AUC) za Modigraf iznosila približno 18% više nego za Prograf kapsule kad su se primijenjeni kao jednokratne doze.
In healthy subjects the systemic exposure to tacrolimus(AUC) for Modigraf was approximately 18% higher than that for Prograf capsules when administered as single doses.

Dvije formulacije takrolimusa, Advagraf i Prograf, imaju sličan odnos između najnižih izmjerenih koncentracija(C24) i sistemske izloženosti AUC 0-24.
The relationship between tacrolimus trough levels(C24) and systemic exposure(AUC 0-24) is similar between the two formulations Advagraf and Prograf.

Povjerenstvo Agencije za humane lijekove(CHMP) odlučilo je da odobrena doza Envarsus-a posjeduje kvalitetu, sigurnost i djelotvornost usporedive s Advagraf-om i Prograf-om.
The Agency's Committee for Medicinal Products for Human Use(CHMP) decided that the approved doses of Envarsus have been shown to have a comparable quality, safety and effectiveness to Advagraf and Prograf.

Ako nisu moguće jednake doze, potrebno je zaokružiti ukupnu dnevnu dozu Prografa na najbližu moguću veličinu, s time da se viša doza daje ujutro, a niža navečer.
If equal doses are not possible, the total daily dose of Prograf should be rounded-up to the nearest amount possible, with the higher dose given in the morning and the lower dose in the evening.

Čini se da nema značajne razlike u uzorku nuspojava za koje se sumnja da su uzročno povezane s ispitivanim lijekom, između Envarsusa primijenjenog jedanput na dan i kapsula takrolimusa s trenutnim oslobađanjem Prograf.
There appears to be no significant difference in the pattern of adverse events suspected to be causally related to study drug between once daily Envarsus and tacrolimus immediate-release capsules Prograf.

Djelotvornost i sigurnost primjene Advagrafa i Prografa, oba u kombinaciji s mikofenolat mofetilom(MMF) i kortikosteroidima, uspoređivala se u 667 de novo primatelja presatka bubrega.
The efficacy and safety of Advagraf and Prograf, both in combination with mycophenolate mofetil(MMF) and corticosteroids, was compared in 667 de novo kidney transplant recipients.

Viša Cavg(~50%), smanjena fluktuacija vršne i najniže koncentracije(Cmax/Cmin) te dulji Tmax uočeni su za Envarsus u usporedbi s oba takrolimusa: s trenutnim oslobađanjem(Prograf) i takrolimusom koji se uzima jedanput na dan Advagraf.
Higher Cavg(~50%), reduced peak trough fluctuation(Cmax/Cmin) and a longer Tmax were seen for Envarsus when compared with both, tacrolimus immediate-release formulation(Prograf) and a tacrolimus once daily formulation Advagraf.

Slično tome, za prebacivanje bolesnika s Prograf kapsula na Modigraf granule ukupna dnevna doza Modigrafa treba po mogućnosti biti jednaka ukupnoj dnevnoj dozi Prografa..
Similarly, for conversion of patients from Prograf capsules to Modigraf granules, the total daily Modigraf dose should preferably be equal to the total daily Prograf dose.

Ispitivanja nisu bila provedena s prelaskom bolesnika sa Adagrafa na Envarsus, međutim podaci dobiveni kod zdravih dobrovoljaca ukazuju da se može primijeniti ista brzina prelaska kao i kod prelaska s Prografa na Envarsus.
No studies have been conducted with conversion of patients from Advagraf to Envarsus; however, data from healthy volunteers would suggest that the same conversion rate is applicable as with the conversion from Prograf to Envarsus.

Djelotvornost i sigurnost Envarsusa i Prografa, oba u kombinaciji s mikofenolat mofetilom ili mikofenolatnatrijem i kortikosteroidima, uspoređena je u 324 stabilna primatelja presatka bubrega.
The efficacy and safety of Envarsus and Prograf, both in combination with mycophenolate mofetil(MMF) or mycophenolate sodium(MPS) and corticosteroids, was compared in 324 stable kidney transplant recipients.

Stopa lokalno interpretirane akutne reakcije odbacivanja potvrđene biopsijom(BPAR), tijekom 360 dana ispitivanja iznosila je 1,2% u skupini koja je primala Envarsus(N=162) nakon prebacivanja s Prografa u omjeru doza od 1: 0,7(mg: mg) i 1,2% u skupini koja je zadržana na Prografu N=162.
The event rate for locally read biopsy-confirmed acute rejection(BPAR) during the 360 day study was 1.2% in the Envarsus group(N=162) post conversion from Prograf at a dose ratio of 1:0.7(mg: mg) and 1.2% in the group maintained on Prograf N=162.

Djelotvornost i sigurnost primjene Prografa, ciklosporina i Advagrafa, svih u kombinaciji s indukcijom baziliksimab protutijelima, MMF-om i kortikosteroidima, uspoređivala se u 638 de novo primatelja presatka bubrega.
The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant recipients.

Incidencija neuspješne djelotvornosti nakon 12 mjeseci(definirane kao smrt, gubitak presatka, biopsijom potvrđeno akutno odbacivanje ili bolesnici odustali/isključeni tijekom praćenja) iznosila je 14,0% u skupini koja je primala Advagraf(N=214), 15,1% u skupini koja je primala Prograf(N=212) i 17,0% u skupini koja je primala ciklosporin N=212.
The incidence of efficacy failure at 12 months(defined as death, graft loss, biopsy-confirmed acute rejection, or lost to follow-up) was 14.0% in the Advagraf group(N=214), 15.1% in the Prograf group(N=212) and 17.0% in the ciclosporin group N=212.

U stabilnih bolesnika koji su prešli s kapsula Prografa(dvaput na dan) na kapsule Advagrafa(jedanput na dan) u omjeru ukupne dnevne doze 1:1(mg: mg), sistemska izloženost takrolimusu(AUC0-24) bila je oko 10% niža za Advagraf od one za Prograf.
In stable patients converted from Prograf capsules(twice daily) to Advagraf(once daily) on a 1:1(mg: mg) total daily dose basis, the systemic exposure to tacrolimus(AUC0-24) for Advagraf was approximately 10% lower than that for Prograf.

Ako se u bolesnika bez indukcije protutijela terapija takrolimusom započne intravenski, preporučena početna doza je 0, 03- 0, 05 mg/kg na dan(s Prograf 5 mg/ml koncentratom za otopinu za infuziju) u obliku kontinuirane 24-satne infuzije s ciljem da se postignu koncentracije takrolimusa u punoj krvi od 15 do 25 nanogram/ml.
In patients without antibody induction, if tacrolimus therapy is initiated intravenously, the recommended starting dose is 0.03- 0.05 mg/kg/day(with Prograf 5 mg/ml concentrate for solution for infusion) as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15- 25 nanogram/ml.

Djelotvornost i sigurnost Envarsusa i Prografa, oba u kombinaciji s mikofenolat mofetilom, kortikosteroidima, i antagonistima receptora za IL-2 prema standardima njege, uspoređena je u randomiziranom, dvostruko slijepom ispitivanju s dvostrukim placebom s 543 bolesnika s de novo transplantiranim bubrezima.
The efficacy and safety of Envarsus and Prograf, both in combination with Mycophenolate Mofetil(MMF) corticosteroids, and IL-2 receptor antagonist as per the standard of care was compared in a randomised, double-blind, double-dummy study, in 543 de novo kidney transplant recipients.

Najniže razine takrolimusa u krvi treba također pažljivo pratiti kad se opaze klinički znakovi toksičnosti ili akutnog odbacivanja, nakon prebacivanja s Modigraf granula na Prograf kapsule, nakon prilagodbe doze, nakon promjene imunosupresivnog režima ili kod istodobne primjene tvari koje mogu promijeniti koncentracije takrolimusa u punoj krvi vidjeti dio 4.5.
Blood trough levels of tacrolimus should also be closely monitored when clinical signs of toxicity or acute rejection are observed, following conversion between Modigraf granules to Prograf capsules, dose adjustments, changes in the immunosuppressive regimen, or co-administration of substances which may alter tacrolimus whole blood concentrations see section 4.5.

Prelazak bolesnika koji su primali Prograf ili Advagraf na Envarsus- bolesnici s alogenim presatkom U bolesnika s alogenim presatkom koji uzimaju Prograf( s trenutnim oslobađanjem) dva puta na dan ili Advagraf( jedanput na dan), a moraju prijeći na Envarsus koji se uzima jedanput na dan, prelazak treba biti u omjeru ukupne dnevne doze 1: 0, 7( mg: mg), stoga doza održavanja Envarsusa treba biti 30% manja od doze Prografa ili Advagrafa.
Conversion of Prograf- or Advagraf-treated patients to Envarsus- allograft transplant patients Allograft transplant patients maintained on twice daily Prograf( immediate-release) or Advagraf( once daily) dosing requiring conversion to once daily Envarsus should be converted on a 1:0.7( mg: mg) total daily dose basis and the Envarsus maintenance dose should, therefore, be 30% less than the Prograf or Advagraf dose.